You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approach
|
|---|---|
| Published in |
Orphanet Journal of Rare Diseases, September 2013
|
| DOI | 10.1186/1750-1172-8-149 |
| Pubmed ID | |
| Authors |
Robert A Stockley, Marc Miravitlles, Claus Vogelmeier, Behalf of Alpha One International Registry (A.I.R.) |
| Abstract |
Intravenous augmentation therapy is the only specific treatment available for emphysema associated with alpha-1 antitrypsin deficiency. Despite large observational studies and limited interventional studies there remains controversy about the efficacy of this treatment due to the impracticality of conducting adequately powered studies to evaluate the rate of decline in lung function, due to the low prevalence and the slow progression of the disease. However, measurement of lung density by computed tomography is a more specific and sensitive marker of the evolution of emphysema and two small placebo-controlled clinical trials have provided evidence supporting a reduction in the rate of decline in lung density with augmentation therapy. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 33% |
| Mexico | 1 | 33% |
| Unknown | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 2 | 67% |
| Members of the public | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 68 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 3% |
| United Kingdom | 1 | 1% |
| Spain | 1 | 1% |
| Germany | 1 | 1% |
| Unknown | 63 | 93% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 11 | 16% |
| Student > Ph. D. Student | 8 | 12% |
| Student > Bachelor | 8 | 12% |
| Librarian | 4 | 6% |
| Other | 4 | 6% |
| Other | 15 | 22% |
| Unknown | 18 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 24 | 35% |
| Agricultural and Biological Sciences | 8 | 12% |
| Biochemistry, Genetics and Molecular Biology | 6 | 9% |
| Economics, Econometrics and Finance | 3 | 4% |
| Business, Management and Accounting | 2 | 3% |
| Other | 5 | 7% |
| Unknown | 20 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 November 2023.
All research outputs
#4,659,861
of 25,374,917 outputs
Outputs from Orphanet Journal of Rare Diseases
#644
of 3,105 outputs
Outputs of similar age
#39,404
of 215,077 outputs
Outputs of similar age from Orphanet Journal of Rare Diseases
#9
of 51 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. Compared to these this one has done well and is in the 81st percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,105 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.2. This one has done well, scoring higher than 79% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 215,077 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 51 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 82% of its contemporaries.